Edinburgh Molecular Imaging
Edinburgh
About Edinburgh Molecular Imaging
Edinburgh Molecular Imaging, a Scottish (UK) developer of systemic radiotherapy with cross cancer potential targeting c-Met, was founded in 2014. Originally EMI developed fluorescent optical imaging agents (EMI-137) for detection and surgical guidance of cancer. EMI-137 has passed successfully stage 2b in CRC. In 2019 the company transformed itself into therapeutics, using its c-Mat targeting platform to develop a systemic radiotheragnostic pair [Ga68]EMP-10X / [Lu177/Ac225]EMP-10X. PoC in 16 patiens has been achieved and clinical development has started. The EM Imaging team has decades of documented success in imaging agent discovery and development with expertise spanning medicinal chemistry, biochemistry and cell biology, along with direct clinical expertise. The team has expertise in the clinical development, FDA, EMA approvals, US and EU reimbursement, and broad commercialization in US and EU.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.6M
- Last round: Series Unknown (Dec 2019)
- Website: emimaging.com
- Phone: +44 131 658 5306
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/edinburgh-molecular-imaging-151681 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.